{"id":849467,"date":"2025-05-09T07:04:35","date_gmt":"2025-05-09T11:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-expands-industry-leading-immunology-pipeline-with-new-first-in-class-oral-irf5-degrader-program-with-potential-to-address-multiple-immuno-inflammatory-diseases\/"},"modified":"2025-05-09T07:04:35","modified_gmt":"2025-05-09T11:04:35","slug":"kymera-therapeutics-expands-industry-leading-immunology-pipeline-with-new-first-in-class-oral-irf5-degrader-program-with-potential-to-address-multiple-immuno-inflammatory-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-expands-industry-leading-immunology-pipeline-with-new-first-in-class-oral-irf5-degrader-program-with-potential-to-address-multiple-immuno-inflammatory-diseases\/","title":{"rendered":"Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases"},"content":{"rendered":"
\n

\n IRF5 program strengthens Kymera\u2019s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug<\/em>\n <\/p>\n

\n IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others<\/em>\n <\/p>\n

\n KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA <\/em>\n <\/p>\n

\n IND-enabling studies are ongoing with Phase 1 testing expected to begin in early 2026<\/em>\n <\/p>\n

\n Company to hold video webcast today at 10:00 a.m. ET as part of the release of first quarter 2025 results<\/em>\n <\/p>\n

WATERTOWN, Mass., May 09, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc.<\/a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today unveiled a new wholly-owned program within its industry-leading oral immunology pipeline. KT-579, a highly potent, selective, first-in-class development candidate, targets IRF5, an essential signaling node in genetically and clinically validated immune pathways driving inflammation in many diseases with no or suboptimal oral options.\u00a0The new program serves as a valuable addition to the Company’s current portfolio, positioned to target multiple common immuno-inflammatory diseases with the potential to expand access to oral systemic advanced therapies for broader patient populations. Kymera will share preclinical data and outline upcoming milestones for KT-579 during a video webcast this morning.<\/p>\n

\u201cWe\u2019re excited to unveil KT-579 as the latest addition to our paradigm-shifting oral immunology portfolio, providing a complementary immunoregulatory mechanism to our existing pipeline. IRF5 is a master regulator of immunity, and we believe blocking its activity with our degrader has the potential to deliver a transformative oral option in multiple chronic, debilitating rheumatic and autoimmune diseases,\u201d said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. \u201cThe compelling data we have generated demonstrating activity in human primary cells, patient cell samples, and preclinical animal models showcases, for the first time in industry, that targeting IRF5 can lead to correcting immune dysregulation in a disease specific way while generally sparing normal cells.\u201d<\/p>\n

Historically an undrugged transcription factor, IRF5 is a master regulator of innate and adaptive immune response pathways involving pro-inflammatory cytokines (TNF\u03b1, IL-6, IL-12, IL-23), B cell activation (autoantibody production), and Type I Interferon (IFN). IRF5 is selectively expressed and activated in specific cell types such as dendritic cells, monocytes, macrophages, and B cells. Its cell- and disease activation-specific profile has the potential to block cell-specific immune dysregulation while sparing normal cell function. IRF5 has been challenging to drug using traditional small molecule inhibitors due to multiple complex activation steps and the high degree of IRF family member homology.<\/p>\n

KT-579, a potent, selective and oral degrader has the potential to be the first IRF5-targeted therapy to deliver a completely novel and potentially transformative treatment option, in many cases superior to pathway biologics, in rheumatic and autoimmune diseases such as lupus, Sj\u00f6gren\u2019s, RA, IBD, among others. Currently in IND-enabling studies, the Company intends to advance KT-579 into Phase 1 clinical testing in early 2026.<\/p>\n

In preclinical studies, KT-579 demonstrated an encouraging profile in human primary cells, patient derived cells, and in vivo<\/em> disease models generally superior to existing standards of care:<\/p>\n